(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Imaging Année : 2012

(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

Résumé

Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major "milestones" of this development, from the first syntheses to the recent first injection in man, are described.
Fichier principal
Vignette du fichier
278306m.pdf (3.18 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-00866975 , version 1 (27-09-2013)

Identifiants

Citer

Nicolas Lepareur, Valérie Ardisson, Nicolas Noiret, Etienne Garin. (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.. International Journal of Molecular Imaging, 2012, 2012, 278306 (9 p.). ⟨10.1155/2012/278306⟩. ⟨hal-00866975⟩
221 Consultations
318 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More